Methylation and colorectal cancer

Journal of Pathology

Volumn 195, Issue 1, 2001, Pages 111-134

  Paulsen, Martina ^a   Ferguson Smith, Anne C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Colorectal cancer; CpG island methylator phenotype; DNA methylation

Indexed keywords

CYTOSINE;

ADENOCARCINOMA; ADENOMA; AGING; CANCER; CANCER MORTALITY; CARCINOGENESIS; CHROMATIN STRUCTURE; CHROMOSOME ABERRATION; COLON ADENOCARCINOMA; COLORECTAL CANCER; CPG ISLAND; DIAGNOSIS; DNA METHYLATION; GENE SILENCING; GENETIC DAMAGE; GENETIC TRANSCRIPTION; GENETICS; HERITABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NEOPLASM; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SMOKING; STATISTICS; THERAPY; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMA; AGED; AGING; CHROMATIN; COLORECTAL NEOPLASMS; CPG ISLANDS; CYTOSINE; DIET; DNA METHYLATION; FEMALE; GENE SILENCING; GENES, APC; GENES, TUMOR SUPPRESSOR; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MODELS, GENETIC; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034807280     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.923     Document Type: Review

References (251)

1. Cancer statistics, 1996
2. Molecular pathology of colorectal cancer
3. Cancer cells exhibit a mutator phenotype
4. Foulds' dangerous idea revisited: The multistep development of tumors 40 years later
5. A genetic model for colorectal tumorigenesis
6. Lessons from hereditary colorectal cancer
7. The age of cancer
8. Hypomethylation of ras oncogenes in primary human cancers
9. Alterations in DNA methylation: A fundamental aspect of neoplasia
10. CpG island methylator phenotype in colorectal cancer
11. DNA methylation and gastro-intestinal malignancies: Functional consequences and clinical implications
12. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3
13. Cancer Research Campaign
14. ABC of colorectal cancer. Epidemiology
15. Colon cancer: A review of the epidemiology
16. ABC of colorectal cancer. Molecular basis for risk factors
17. Colorectal tumors
18. A tale of four syndromes: Familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome
19. Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps
20. Genetic pathways in colorectal and other cancers
21. The mutation rate and cancer
22. A mathematical model for the age distribution of cancer in man
23. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
24. CpG-rich islands and the function of DNA methylation
25. Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer
26. CpG islands in vertebrate genomes
27. The essentials of NA methylation
28. The inheritance of epigenetic defects
29. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
30. X chromosome inactivation and DNA methylation
31. Role for DNA methylation in genomic imprinting
32. Gene number, noise reduction and biological complexity
33. Mobile elements and the human genome
34. Methylation-induced repression - Belts, braces and chromatin
35. Repeat-induced gene silencing in mammals
36. Hypomethylation of DNA from benign and malignant human colon neoplasms
37. Evaluation of global DNA hypomethylation in human colon cancer tissues by immunohistochemistry and image analysis
38. DNA hypomethylation leads to elevated mutation rates
39. DNA methylation and genetic instability in colorectal cancer cells
40. Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multi-drug resistance 1 gene in human cancer cells
41. Site-specific DNA methylation contributes to neurotensin/neuromedin N expression in colon cancers
42. Patterns of methylation of the c-myc gene in human colorectal cancer progression
43. Abnormal methylation of the calcitonin gene in human colonic neoplasms
44. The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia
45. DNA methylation: A molecular lock
46. Allele-specific hypermethylation of the retino-blastoma tumor-suppressor gene
47. Cancer epigenetics comes of age
48. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
49. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability
50. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure
51. Senescence of nickel-transformed cells by an X chromosome: Possible epigenetic control
52. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: A new model for epigenetic carcinogens
53. The influence of age on colonic epithelial cell proliferation
54. CpG island methylation in aging and cancer
55. Genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands
56. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification
57. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
58. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
59. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
60. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression
61. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction
62. DNA methylator and mismatch repair phenotypes are not mutually exclusive in colorectal cancer cell lines
63. MethyLight: A high-throughput assay to measure DNA methylation
64. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines
65. Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers
66. CpG-island methylation in aging and cancer
67. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in the human colon
68. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis
69. Ageing and DNA methylation in colorectal mucosa and cancer
70. The epigenetics of colorectal cancer
71. Aging, methylation and cancer
72. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer
73. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines
74. How does DNA methyltransferase cause oncogenic transformation?
75. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors
76. Epigenetic phenotypes distinguish microsatellite-stable and -unstable colorectal cancers
77. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
78. The environment and disease: Cause or association
79. MeCP2 is a transcriptional repressor with abundant sites in genomic chromatin
80. Nucleosome assembly on methylated CGG triplet repeats in the fragile X mental retardation gene 1 promoter
81. CpG methylation remodels chromatin structure in vitro
82. CpG methylation of the cAMP-responsive enhance/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation
83. Relationships between chromatin organization and DNA methylation in determining gene expression
84. Purification, sequence and cellular localization of a novel chromosomal protein that binds to methylated DNA
85. Identification and characterization of a family of mammalian methyl-CpG binding proteins
86. Mammalian methyltransferases and methyl-CpG-binding domains: Proteins involved in DNA methylation
87. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
88. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
89. DNA methylation directs a time-dependent repression of transcriptional initiation
90. Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene
91. What's up and down with histone deacetylation and transcription?
92. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex
93. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation
94. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites
95. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
96. Transcriptional co-regulators in development
97. Histone acetylation and transcriptional regulatory mechanisms
98. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics
99. Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyl-transferase gene
100. The DNA methyltransferases of mammals
101. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases
102. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development
103. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase
104. A mammalian protein with specific demethylase activity for mCpG DNA
105. DNA methylation is a reversible biological signal
106. Increased cytosine DNA-methyltransferase activity during colon cancer progression
107. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer
108. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis
109. Limited up-regulation of DNA methyltransferase in human colon cancer reflecting increased cell proliferation
110. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells
111. Suppression of intestinal neoplasia by DNA hypomethylation
112. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligonucleotide
113. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis
114. Transcriptional regulation of the human DNA methyltransferase (dnmt1) gene
115. Role of DNA 5-methylcytosine transferase in cell transformation by fos
116. Regulation of DNA methylation by the Ras signaling pathway
117. CpG methylation is maintained in human cancer cells lacking DNMT1
118. CpG island hypermethylation in human colorectal tumours is not associated with DNA methyltransferase overexpression
119. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1
120. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/Sdi1)
121. Down-regulation of human DNA-(cytosine-5) methyl-transferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cipl) by distinct mechanisms
122. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome
123. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene
124. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
125. The establishment and maintenance of DNA methylation patterns in mouse somatic cells
126. Promoter-region hypermethylation and gene silencing in human cancer
127. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation
128. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements
129. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators
130. Cytosine methylation targeted to predetermined sequences
131. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters
132. Feedback regulation of DNA methyltransferase gene expression by methylation
133. DNA methylation properties: Consequences for pharmacology
134. DNA methylation, genomic imprinting and cancer
135. Maintenance of genomic methylation requires a SWI2/SNF2-like protein
136. Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis
137. Molecular cloning, mapping and characterization of a novel human gene, MTA1-L1, showing homology to a metastasis-associated gene, MTA1
138. Do intrinsic sex differences in lower alimentary tract physiology influence the sex-specific risks of bowel cancer and other biliary and intestinal diseases
139. Incidence of colorectal adenocarcinoma by anatomic subsite. An epidemiologic study of time trends and racial differences in the Detroit, Michigan area
140. Dietary selenium and arsenic affect DNA methylation in vitro in caco-2 cells and in vivo in rat liver and colon
141. Methylenetetrahydrofolate reductase, diet and risk of cancer
142. Are dietary factors involved in DNA methylation associated with colon cancer?
143. Hypermethylation of tumor suppressor genes in cancer
144. Aberrant methylation of gene promoters in cancer - Concepts, misconcepts, and promise
145. Genetic and epigenetic contributions to colorectal cancer
146. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
147. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma
148. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer
149. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma
150. Mutations and altered expression of p16INK4 in human cancer
151. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
152. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
153. Cell cycle regulator potentially involved in the genesis of many tumour types
154. Role of the p16 tumor suppressor gene in cancer
155. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancer
156. Abundance of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer
157. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: Association with DNA replication error and shorter survival
158. Association of K-ras mutations with p16 methylation in human colon cancer
159. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status
160. Hypermethylation can selectively silence individual p16ink4A alelles in neoplasia
161. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colities
162. Cancer cell cycles
163. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
164. p19ARF links the tumour suppressor p53 to Ras
165. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B
166. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras
167. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer
168. The cat and mouse games that genes, viruses and cells play
169. DNA mismatch repair genes and colorectal cancer
170. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients
171. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
172. Genetic instability in colorectal cancers
173. Genomic imprinting proposed as a surveillance mechanism for chromosome loss
174. Genetic instabilities in human cancers
175. Hairpins are formed by the single DNA strands of the fragile X triplet repeats: Structure and biological implications
176. Association between CpG island methylation and microsatellite instability in colorectal cancer
177. Epigenetic lesions causing genetic lesions in human cancer: Promoter hypermethylation of DNA repair genes
178. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
179. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
180. Allelic loss and DNA methylation at DNA mismatch repair loci in sporadic colorectal cancer
181. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
182. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers
183. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI + sporadic colorectal cancers
184. Defective hMSH2/hMLH1 protein expression is seen infrequently in ulcerative colitis associated colorectal cancers
185. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1
186. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
187. Apoptosis induced by overexpression of hMSH2 or hMLH1
188. DNA repair: Enzymatic mechanisms and relevance to drug response
189. Mammalian O6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents
190. Loss of MGMT and hMLH1 expression in colon cancers
191. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia
192. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers
193. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene
194. Regulation of the human O6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300
195. Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells
196. Low O6-alkylguanine DNA-alkyltransferase activity in normal colorectal tissue is associated with colorectal tumours containing containing a GC ← AT transition in the K-ras oncogene
197. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis
198. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
199. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
200. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
201. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
202. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs
203. Inhibition of cyclooxygenase-2 expression by p53
204. Methylation and silencing of the thrombospondin-1 promoter in human cancer
205. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain and other human cancers
206. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome
207. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome
208. 5′-CpG island methylation of the LKB1/STK11 promoter and allelic loss of chromosome 19p13.3 in sporadic colorectal cancer
209. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia
210. No SMAD4 hypermethylation in colorectal cancer
211. Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma
212. Hypermethylation of WT1 and calcitonin gene promoter regions at chromosome 11p in human colorectal cancer
213. ABC of colorectal cancer. Adjuvant chemotherapy
214. Effects of 5-azacytidine and its 2′-deoxyderivative on cell differentiation and DNA methylation
215. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase
216. DNA methylation changes in haematologic malignancies: Biologic and clinical implications
217. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome
218. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of hMLH1 gene promoter
219. Apicidin, a histone deacetylase inhibitor, inhibitors proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin
220. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
221. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma
222. Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo
223. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea
224. Mismatch repair proficiency and in vitro response to 5-fluorouracil
225. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
226. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
227. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
228. Overall deregulation in gene expression as a novel indicator of tumor aggressiveness in colorectal cancer
229. p53 and K-ras gene mutations correlated with tumor aggressiveness but are not of routine prognostic value in colorectal cancer
230. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer
231. Replication error in colorectal carcinoma: Association with loss of heterozygosity at mismatch repair loci and clinicopathological variables
232. Epigenetics of inflammatory bowel disease
233. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms
234. DNA hypomethylation in inflammatory arthritis: Reversal with methotrexate
235. Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells
236. The effect of sodium butyrate on histone modification
237. Short-chain fatty acids in ulcerative colitis
238. Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region
239. Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors
240. Calcium - A life and death signal
241. Number of CpG islands and genes in human and mouse
242. MethDB - A public database for DNA methylation data
243. Predicting lung cancer by detecting aberrant promoter methylation in sputum
244. Detection of aberrant promoter methylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
245. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colorectal cancer
246. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability
247. Instability of X chromosome methylation in aberrant crypt foci of the human colon
248. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence
249. A bird's eye view of global methylation
250. Methylation meets genomics